Compare Organon & Co. Common Stock (OGN) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $68.76 (market cap $323.80B). The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is far larger — about 89.4× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Vanguard Tax Managed Fund FTSE Developed Markets ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Vanguard Tax Managed Fund FTSE Developed Markets ETF for 132 Days on average.
| OGN | VEA | |
|---|---|---|
Market Cap | $3.62B | $323.80B |
Volume | 2,892,999 | 7,840,398 |
Sector | Health | — |
52-Week High | $13.81 | $73.79 |
52-Week Low | $5.70 | $58.90 |
Typical Hold Time | 0 Days | 132 Days |
Enterprise Value | $11.04B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
VEA trades at $70.06 with minimal daily movement (+0.16%). The technical outlook is bearish with moving averages signaling weakness, though oscillators remain neutral. Recent news highlights VEA's competitive advantages including a low 0.03% expense ratio and higher dividend yield compared to peers. Institutional activity shows mixed signals with some firms increasing positions while others reduced exposure.
The ETF's focus on developed international markets provides stability but faces currency and geopolitical risks. Current bearish technical signals suggest near-term caution, though the fund's cost efficiency and diversification benefits support long-term international exposure. Key risks include global economic slowdowns and currency fluctuations affecting returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
